Dabrafenib

Dabrafenib is an oral targeted anticancer medicine belonging to the BRAF kinase inhibitor class. It selectively inhibits abnormal BRAF signaling, particularly signaling driven by activating BRAF V600 mutations, which can promote uncontrolled cancer-cell growth through the MAPK pathway. By blocking this pathway, dabrafenib can reduce downstream signaling involved in tumor-cell proliferation and survival. Dabrafenib is available as oral capsules and tablets for oral suspension, with administration depending on the approved formulation and patient population. It is used as a single agent for selected BRAF V600E mutation-positive melanoma and, more commonly in several indications, in combination with the MEK inhibitor trametinib to provide dual pathway inhibition. Its clinical importance comes from the ability to provide biomarker-directed treatment for cancers in which a BRAF V600 mutation is an important driver of disease. Appropriate molecular testing is therefore an essential part of treatment selection, and the specific mutation requirement depends on the indication and applicable regulatory authority.

Dabrafenib was developed as a selective inhibitor of mutant BRAF kinase and became an important targeted therapy for tumors driven by BRAF V600 alterations. The U.S. Food and Drug Administration granted its initial approval in May 2013 for patients with unresectable or metastatic melanoma with a BRAF V600E mutation detected by an FDA-approved test. Subsequent FDA approvals expanded its use in combination with trametinib for BRAF V600E or V600K melanoma, adjuvant melanoma following complete resection with lymph-node involvement, metastatic BRAF V600E non-small cell lung cancer, locally advanced or metastatic BRAF V600E anaplastic thyroid cancer, pediatric BRAF V600E low-grade glioma, and certain previously treated unresectable or metastatic BRAF V600E solid tumors with no satisfactory alternative treatment options. The European Medicines Agency issued the initial marketing authorisation for Tafinlar in 2013, with subsequent expansion of its authorised uses. In 2026, the EMA’s Committee for Medicinal Products for Human Use adopted a positive opinion for dabrafenib in combination with trametinib for adults with locally advanced or metastatic BRAF V600E differentiated thyroid cancer that is refractory to or unsuitable for radioactive iodine and has progressed after systemic therapy. Major clinical development programs included BREAK studies in melanoma, COMBI-d and COMBI-v for dabrafenib plus trametinib in melanoma, BRF113928 in BRAF V600E non-small cell lung cancer, COMBI-AD in resected melanoma, and the ROAR basket study in several BRAF V600E-mutated rare cancers.

Dabrafenib is used according to the documented BRAF mutation status and the indication-specific regulatory requirements. As a single agent, it is approved in the United States for unresectable or metastatic melanoma with a BRAF V600E mutation. In combination with trametinib, it is approved for unresectable or metastatic melanoma with BRAF V600E or V600K mutations and for adjuvant treatment of melanoma with BRAF V600E or V600K mutations and lymph-node involvement following complete resection. The combination is also used for metastatic non-small cell lung cancer with a BRAF V600E mutation and for locally advanced or metastatic anaplastic thyroid cancer with a BRAF V600E mutation when there are no satisfactory locoregional treatment options. FDA labeling additionally includes adults and pediatric patients aged 1 year and older with unresectable or metastatic BRAF V600E solid tumors that have progressed after prior treatment when no satisfactory alternative treatment exists, under accelerated approval, and pediatric patients aged 1 year and older with BRAF V600E low-grade glioma requiring systemic therapy. European indications differ in some respects and include adult BRAF V600-mutated melanoma, advanced BRAF V600-mutated non-small cell lung cancer, pediatric BRAF V600E glioma, and the recently recommended differentiated thyroid cancer indication. Treatment may therefore be given as monotherapy or as part of combination therapy depending on the cancer type, mutation, patient age, and applicable regulatory label.

Dabrafenib is administered orally, and the standard adult dose for most approved adult indications is 150 mg twice daily. When used with trametinib, dabrafenib is taken on a regular twice-daily schedule while trametinib is generally administered once daily according to its prescribing information. Dabrafenib should be taken on an empty stomach, generally at least 1 hour before or 2 hours after a meal, and doses should be taken at approximately consistent times each day. Pediatric dosing is weight-based and differs according to age, body weight, formulation, and indication, so it should be determined from the applicable pediatric prescribing information rather than extrapolated from the adult dose. In the adjuvant melanoma setting, combination treatment is generally administered for up to 12 months unless recurrence or unacceptable toxicity occurs. For unresectable or metastatic disease, treatment is generally continued until disease progression or unacceptable toxicity. Dose interruption, reduction, or discontinuation may be required for clinically significant adverse reactions, and treatment should be supervised by clinicians experienced in anticancer therapy.

Common adverse effects vary according to whether dabrafenib is used alone or with trametinib and according to the treated cancer. Frequently reported effects include fever or pyrexia, fatigue, headache, joint or muscle pain, nausea, vomiting, diarrhea, chills, rash, dry skin, decreased appetite, cough, and skin-related changes. Dabrafenib monotherapy can also be associated with hyperkeratosis, papillomas, hair loss, and palmar-plantar erythrodysesthesia. Fever is particularly important with the dabrafenib and trametinib combination and may sometimes be accompanied by chills, dehydration, low blood pressure, or kidney-related complications. Many adverse effects can be managed through supportive treatment, temporary treatment interruption, dose modification, or other measures under appropriate medical supervision.

Important risks include development of new primary malignancies, including cutaneous and non-cutaneous malignancies, because BRAF inhibition can promote proliferation in certain BRAF-wild-type cells. Major hemorrhage, cardiomyopathy, eye inflammation such as uveitis, serious febrile reactions, severe skin toxicity, hyperglycemia, and hemolytic anemia in patients with glucose-6-phosphate dehydrogenase deficiency have also been reported. Dabrafenib can cause serious fever-related reactions, particularly when combined with trametinib, and patients should be assessed for complications such as dehydration, hypotension, renal dysfunction, or severe systemic symptoms. Dabrafenib can cause fetal harm, so pregnancy status and reproductive counselling are important before and during treatment. Treatment may need to be interrupted, dose-reduced, or permanently discontinued depending on the severity and persistence of an adverse reaction. Visual symptoms, significant bleeding, new skin lesions, severe rash, persistent fever, cardiac symptoms, or other serious clinical changes require prompt medical assessment.

Before treatment, the relevant BRAF V600 mutation should be confirmed using an appropriate validated test according to the indication and applicable regulatory requirements. Baseline assessment commonly includes clinical examination, blood counts and chemistry testing, glucose evaluation where appropriate, and cardiovascular assessment when dabrafenib is used with trametinib. Because the combination can affect cardiac function, left ventricular ejection fraction should be assessed before treatment and monitored during therapy according to the applicable prescribing information. Patients should also be monitored for ocular symptoms, skin changes, fever, and signs of bleeding. Dabrafenib is metabolised through pathways involving CYP3A4 and CYP2C8 and can induce several drug-metabolising enzymes, meaning that clinically important interactions can occur with strong enzyme inhibitors or inducers and with certain medicines whose effectiveness depends on CYP-mediated metabolism. Contraceptive counselling is important because dabrafenib may reduce the effectiveness of some hormonal contraceptives, and effective non-hormonal contraception is generally recommended during treatment and for the appropriate period after treatment. Pregnancy should be avoided because of potential fetal harm. Vaccination plans should be reviewed before and during treatment, with decisions regarding live or attenuated vaccines made according to the patient's clinical situation and current prescribing guidance.

Prescribers should confirm the required BRAF mutation before starting therapy and ensure that the selected regimen matches the specific tumor type, disease stage, patient age, and applicable regulatory indication. When dabrafenib is combined with trametinib, clinicians should establish baseline cardiac function and continue appropriate monitoring of cardiac, ocular, dermatologic, metabolic, and febrile complications. Patients should be counselled to take dabrafenib consistently on an empty stomach and to report persistent fever, chills, visual changes, new or changing skin lesions, bleeding, shortness of breath, or other significant symptoms promptly. Pharmacists should review the complete medication list for CYP3A4 and CYP2C8 inhibitors or inducers and for medicines whose concentrations may be affected by dabrafenib enzyme induction. Reproductive counselling and review of contraceptive effectiveness are important, and coordination between oncology, pathology, pharmacy, and other relevant specialties helps ensure appropriate biomarker confirmation, dosing, toxicity management, and treatment continuity.